Shifting Trends in Severe Asthma Biologics: Daily Dose
Your daily dose of the clinical news you may have missed.
What to Know Before AAD 2025: Product Snapshots of Nonsteroidal Topical Treatments for Eczema
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
WHO Recommends Flu Vaccine Composition for 2025-26 Northern Hemisphere Season as US HHS Cancels ACIP, VRBAC Meetings
Two official US vaccine planning meetings cancelled in February is an "unprecedented situation," said NFID medical director Robert Hopkins, Jr, MD.
Omalizumab Efficacy and Safety Shown Superior to OIT in First Head-to-Head Multi-Food Allergy Trial
Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.
Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy
The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Pediatric Anaphylaxis Study
Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.
Atopic Dermatitis Primer for AAD 2025: Dermatologist Mona Shahriari, MD, Explains the Rise in Prevalence
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
Dupilumab Reduces Specific IgE to Foods at 12 and 24 Months in Small Study
AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.
FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature
The Loss of Pulse Detection feature will begin rolling out in the US late next month.
Nektar Therapeutics Completes Enrollment for Phase 2b Alopecia Areata Trial
The company announced completion of target enrollment in the REZOLVE-AA study of rezpegaldesleukin in people with severe-to-very-severe alopecia areata.
FDA Greenlights New Wearable Treatment for Parkinson Disease: Daily Dose
Perimenopause Symptoms May Affect More Than Half of Women as Young as Age 30
Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.
American Academy of Dermatology 2025 Prep: A Dermatologist Considers When Atopic Dermatitis Referral from Primary Care is Indicated
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
The Superbug Challenge: Medicine's Essential Fight Against Antimicrobial Resistance
A medical director of antimicrobial stewardship at a large metropolitan health system highlights the dangers of AMR and how she believes the pharmaceutical industry could help.
Measles Outbreak Explained: Disease History, Vaccine Breakthrough and 2025 Resurgence
The 2025 measles outbreak in Texas has reignited discussion surrounding vaccine-preventable diseases and the importance of maintaining high immunization rates.
Study Finds Telehealth Use in Depression Skews Towards Higher-Wealth Patients
Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.
FDA Accepts Supplemental New Drug Application for Uzedy for Bipolar I Disorder
The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.
Transdermal Peanut Patch Shows Lasting Allergy Benefits: Daily Dose
Focus on AAD 2025: Dermatologist Mona Shahriari, MD, Highlights the PCP Role in Atopic Dermatitis Care
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.
